All In Biotech

Drug Trial Radar · NCT00184574

Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes

Comparison of the Effect on Glycemic Control of Biphasic Insulin Aspart 70/30, Biphasic Insulin Aspart 50/50, and Biphasic Insulin Aspart 30/70 All in Combination With Metformin in Subjects With Type 2 Diabetes (the INTENSIMIX Trial).

Last checked: Nov 20, 2026Latest source record: Jan 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 603 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

603

Actual

Start

Apr 2005

Primary completion

Mar 2006

Study completion Mar 2006

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 16, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Europe. This trial aims for a comparison of the effect on glycemic control in subjects with type 2 diabetes of three different premixed insulin analogues given in combination with an oral anti-diabetic drug.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • biphasic insulin aspartDrug

  • metforminDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1cTime frame: after 36 weeks

Locations

108 sites in 18 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Bregenz, Austria

  • Novo Nordisk Investigational Site

    Feldkirch, Austria

  • Novo Nordisk Investigational Site

    Graz, Austria

  • Novo Nordisk Investigational Site

    Salzburg, Austria

  • Novo Nordisk Investigational Site

    Vienna, Austria

  • Novo Nordisk Investigational Site

    Bonheiden, Belgium

  • Novo Nordisk Investigational Site

    Brussels, Belgium

  • Novo Nordisk Investigational Site

    Genk, Belgium

  • Novo Nordisk Investigational Site

    Ghent, Belgium

  • Novo Nordisk Investigational Site

    Liège, Belgium

  • Novo Nordisk Investigational Site

    Pleven, Bulgaria

  • Novo Nordisk Investigational Site

    Sofia, Bulgaria

  • Novo Nordisk Investigational Site

    Brno, Czechia

  • Novo Nordisk Investigational Site

    Hradec Králové, Czechia

  • Novo Nordisk Investigational Site

    Prague, Czechia

  • Novo Nordisk Investigational Site

    Århus C, Denmark

  • Novo Nordisk Investigational Site

    Køge, Denmark

  • Novo Nordisk Investigational Site

    Odense, Denmark

  • Novo Nordisk Investigational Site

    Antibes, France

  • Novo Nordisk Investigational Site

    Boulogne-Billancourt, France

  • Novo Nordisk Investigational Site

    Brest, France

  • Novo Nordisk Investigational Site

    La Rochelle, France

  • Novo Nordisk Investigational Site

    Le Chesnay, France

  • Novo Nordisk Investigational Site

    Lille, France

  • Novo Nordisk Investigational Site

    Metz, France

  • Novo Nordisk Investigational Site

    Mougins, France

  • Novo Nordisk Investigational Site

    Narbonne, France

  • Novo Nordisk Investigational Site

    Nevers, France

  • Novo Nordisk Investigational Site

    Perpignan, France

  • Novo Nordisk Investigational Site

    Bad Heilbrunn, Germany

  • Novo Nordisk Investigational Site

    Beckum, Germany

  • Novo Nordisk Investigational Site

    Berlin, Germany

  • Novo Nordisk Investigational Site

    Dormagen, Germany

  • Novo Nordisk Investigational Site

    Dresden, Germany

  • Novo Nordisk Investigational Site

    Duisburg, Germany

  • Novo Nordisk Investigational Site

    Genthin, Germany

  • Novo Nordisk Investigational Site

    Kippenheim, Germany

  • Novo Nordisk Investigational Site

    München, Germany

  • Novo Nordisk Investigational Site

    Pohlheim, Germany

  • Novo Nordisk Investigational Site

    Saarbrücken, Germany

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.